Takeda is about to buy its way to a number 1 spot in the top tier of drugmakers fielding the most expensive drugs on the planet.
Once its $62 billion Shire buyout goes through, Takeda will be responsible for selling three of the most expensive drugs on the market today, according to the latest list from GoodRx. And that's more than any other manufacturer on the ranking.
The drug pricing analysts at GoodRx decided this year that they needed to double the number of drugs tracked in order to be able to fully capture the growing ranks of therapies that command wholesale prices of more than $25,000 a month.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.Free Subscription